A study of more than 100,000 patients with suspected tuberculosis at 18 sites across India showed that routine testing using Xpert molecular technology rather than the most commonly used — and oldest — diagnostic tool of examining a sputum smear under a microscope, increased detection of TB by 39 percent and led to five times the rate of detecting resistance to a TB treatment medicine.
28 May 2015 | Science Speaks
The regimen is comprised of bedaquiline, which received provisional approval from the U.S. Food and Drug Administration in 2013 to treat drug-resistant tuberculosis, pretomanid a new type of antibacterial drug, and linezolid which is used off-label to treat TB.
15 May 2015 | Science Speaks
WHO today published the new edition of its Model List of Essential Medicines which includes ground-breaking new treatments for hepatitis C, a variety of cancers (including breast cancer and leukaemia) and multi-drug resistant tuberculosis (TB), among others.
11 May 2015 | World Health Organization
Once an active case of extremely drug resistant (XXDR-TB) strain of tuberculosis or totally drug resistant (TDR) TB, 40-year-old Rashid Khan (name changed), has now been completely cured of his disease. Despite having total drug resistance and HIV infection, Khan got cured a few days ago. At one stage he was receiving a cocktail of 18–20 drugs between his HIV and TB regimes. But Bedaquiline made a huge difference in his treatment. He is off medicine now.
24 March 2015 | DNAIndia
The nonprofit medical humanitarian organization Médecins Sans Frontières is recommending that all patients in Swaziland who have tested positive for TB, but rapid molecular testing has found negative for drug-resistance undergo further testing, following findings that a mutation has made more than a quarter of multidrug-resistant strains undetectable by the widely used test.
20 March 2015 | Science Speaks
A new tuberculosis (TB) drug regimen designed to improve options for TB therapy eliminated more bacteria from sputum than standard therapy, worked for people with multi-drug-resistant (MDR) TB, and did so in a quarter of the time, according to data from a phase 2b clinical trial published today in The Lancet. These results are published just as the global phase 3 clinical trial, STAND, designed to bring this regimen through the last stage of testing, has begun. The PaMZ regimen uses pretomanid, a new drug; moxifloxacin, an established antibiotic that is experimental as a TB treatment; and pyrazinamide, an established TB drug. Twenty percent of the TB patients enrolled in NC-002 also were co-infected with HIV and the PaMZ regimen appeared to be effective independent of HIV status. See also http://www.aidsmap.com/Novel-TB-regimen-could-reduce-treatment-duration/page/2892700/
18 March 2015 | Lancet (free registration required)
As many as 1,000 people a day in Europe contract tuberculosis, and slow progress against the disease coupled with rising drug resistance mean the region is unlikely to defeat it until next century, health officials said on Tuesday.
17 March 2015 | Reuters
The compound Nair and his colleagues developed works by binding to magnesium and specific amino acids found within the bacterium, interrupting the production of RNA. They were surprised to discover through preliminary experiments that it also exhibited strong anti-HIV properties, opening the door for dual therapeutic applications.
20 February 2015 | University of Georgia press release
The challenges in addressing the implementation of comprehensive HIV, TB and viral hepatitis prevention and treatment activities in the Eastern Ukraine affected by the warfare is complicated and escalating every week.
11 February 2015 | Stop TB Partnership
Delamanid, only the second tuberculosis drug approved in 40 years by European regulators, uses a new mechanism of action to treat the disease by inhibiting the synthesis of a cell-wall component of Mycobacterium tuberculosis, the bacterium that causes tuberculosis. But patient advocates worry that the new drug may not reach the patients who need it because, according to these advocates, the developer of the drug has failed to aggressively study and market the medication in regions that need it most.
05 February 2015 | Nature Medicine